ACS Fall 2026
Date: August 23-27, 2026
Venue: McCormick Place Convention Center, Chicago, IL – Medicilon Booth #400
【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026
Date: September 10, 2026 (Thursday)
Venue: EL Tower, Ruby Hall, Yangjae, Seoul
World’s First Phase III Positive B7-H3 ADC: Medicilon Congratulates MediLink Therapeutics on NDA Acceptance of Icontamrotamab
On July 18, China’s Center for Drug Evaluation (CDE) accepted the New Drug Application (NDA) for icontamrotamab for injection (Tam-Peli, YL201), a B7-H3-targeted ADC independently developed by MediLink Therapeutics. As the world’s first B7-H3 ADC with positive Phase III results, YL201 has officially entered its launch phase, offering a promising new treatment option for patients […]
Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment
July 28th, 2026
6:00-7:00 PM (PST) | 9:00-10:00 PM (EST)
Medicilon Stands Out at ASMS 2026: Only CRO Selected for Bioanalysis Zone’s ‘Pick of the Posters’
The 74th ASMS Annual Conference on Mass Spectrometry and Allied Topics, held in San Diego from 31 May to 4 June 2026, drew thousands of leading experts from across the global mass spectrometry community. Among the ~3,000 posters presented, Bioanalysis Zone – a premier independent media platform in bioanalytical science – selected just fivefor its […]
Medicilon Congratulates Livzon Pharmaceutical on the Approval of LiYouBao® — China’s Only Export-Qualified r-FSH Injection Meeting Global International Standards
Livzon Pharmaceutical has secured NMPA marketing approval for LiYouBao®, its self-developed recombinant human follicle-stimulating hormone injection. The approval marks a key milestone for Livzon’s fertility pipeline, expanding its market-leading urinary FSH (u-FSH) product portfolio to build a dual u-FSH and recombinant FSH (r-FSH) technology platform. As Livzon’s trusted preclinical CRO partner, Medicilon provided integrated pharmacokinetic, […]
Medicilon Boston R&D Center Awarded Full AAALAC International Accreditation, Further Elevating Global Service Capabilities
Recently, Medicilon Boston R&D Center has successfully passed the rigorous review by AAALAC International and achieved full AAALAC International accreditation. Following the first AAALAC accreditation of its Shanghai R&D Center back in 2009, this renewed recognition proves that Medicilon’s Boston facility has met world-class standards in laboratory animal welfare, ethical supervision, quality management and operational […]
RACI Congress 2026
July 5-10, 2026
Perth Convention & Exhibition Centre, Perth, Western Australia
Medicilon Booth #9
A Sensitive LC–MS Bioanalytical Method for Simultaneous Quantification of Structurally Similar Cyclic Tetrapeptides at the Picogram Level (Download)
Facebook LinkedIn Fill out the form below to download this content.
Quantification of antibody-Conjugated Drug in Cleavable ADCs: A Universal, Automated, and Cost-Effective LC-MS/MS Platform (Download)
Facebook LinkedIn Fill out the form below to download this content.
